Identification of a Prognosis-Related Risk Signature for Bladder Cancer to Predict Survival and Immune Landscapes

Figure 2

Analysis related to high- and low-TNFRSF14-expression group. (a–e) Pathways with differences. (f–g) Drugs with higher sensitivity in the low-TNFRSF14-expression group.

(a)

(b)

(c)

(d)

(e)

(f)

(g)